Higher mean platelet volume (MPV) in diabetic patients has been considered as an emerging risk factor for diabetes related micro-and macrovascular complications. Human paraoxonase 1/arylesterase (PON1), which has antioxidant and antiatherogenic properties, is documented in high oxidative stress conditions like uncontrolled diabetes. The present study aimed to evaluate the relationship between mean platelet volume (MPV) and paraoxonase-1 (PON-1) activity, brachial artery diameter (BAd) and intima media thickness (BA-IMT), in diabetic patients with regard to obesity and diabetic complications. Methods: Two-hundred and one diabetic patients (mean age: 52.4 ± 13.4 years, 73.6% females) were grouped according to obesity and diabetic complications (microvascular and macrovascular). Data on demographics, anthropometrics, diabetic complications, MPV levels, BAd and BA-IMT, and serum paraoxonase and arylesterase activities were recorded. The correlation of MPV values to paraoxonase and arylesterase activities, BAd and BA-IMT was evaluated. Results: Paraoxonase and arylesterase values were 119.8 ± 37.5 U/L and 149.0 ± 39.9 U/L, respectively, with no significant difference in respect of obesity and macrovascular complications. Significantly lower values for paraoxonase (107.5 ± 30.7 vs. 123.9 ± 38.8 U/L, p = 0.007) and arylesterase (132.1 ± 30.2 vs. 154.7 ± 41.2, U/L, p = 0.001) were noted in patients with microvascular complications. MPV values were 9.10 ± 0.87 fL, with no significant difference across the groups and no significant correlation with other parameters.
Introduction
Type 2 diabetes mellitus (T2DM) is a component of metabolic syndrome associated with dyslipidaemia, hypertension, impaired fibrinolysis, and increased pro-coagulation factors. [1] [2] [3] It ranks as the major risk factor for the development of coronary artery disease (CAD) 4, 5 due to the central role of oxidative stress in the pathology of diabetes mellitus. 6, 7 In addition to cardiovascular manifestations, diabetes mellitus has been associated with an increased risk of micro-and macrovascular complications, which are a major cause of morbidity and mortality, 8 as oxidative stress is considered a link between diabetes mellitus and related complications. 9, 10 Human paraoxonase 1/arylesterase (PON1) is a calciumdependent ester hydrolase with paraoxonase, arylesterase and dyazoxonase activities, and antioxidant and anti-atherogenic properties [11] [12] [13] [14] shown to be inversely related to the risk of CVD. 15 Accordingly, a decrease in PON1 activity has been documented in states of high oxidative stress like metabolic syndrome, obesity, uncontrolled diabetes, and dyslipidaemia. 16 It is suggested that decreased PON1 activity in patients with type 2 diabetes mellitus may lead to accelerated atherosclerosis, which causes increased mortality due to CAD.
17-19
The early stages of atherosclerosis consist of functional impairment of endothelial surface with consequent impairment of arterial vasodilation capacity and thickening of the intimamedia space. 20, 21 In addition to carotid intima-media thickness (IMT), which was considered a validated parameter in detecting subclinical atherosclerosis and the severity of coronary atherosclerosis, 20, 21 it was shown that brachial artery IMT (BA-IMT) correlated to carotid IMT. Consequently, it may serve as a marker of cardiovascular risk, and as initial steps of the atherosclerotic process.
22
Mean platelet volume (MPV) is a parameter of platelet size, which is easily determined on routine automated haemogram and is routinely available at a relatively low cost. 23 Higher MPV values, a marker of increased thrombogenicity and atherosclerosis, have been reported in patients with acute myocardial infarction, stroke, diabetes mellitus, congestive heart failure and in hypertensive patients with evidence of target organ damage.
24-26
The volume of thrombocytes is increased with increased thrombocyte activation. It is known that large platelets have more thrombotic potential than smaller ones, they have more intense granules and are more effective metabolically and enzymatically. 27 Moreover, cytokines, such as interleukin-3 or interleukin-6, influence megakaryocyte ploidy and can lead to the production of more reactive, larger platelets at the level of progenitor cells such as megakaryocytes. 28 Altered platelet morphology, function and increased levels of MPV have been reported to lead to the synthesis of more thromboxane 1, 29, 30 in diabetic patients. This condition is currently considered an emerging risk factor for atherothrombosis [31] [32] [33] and is an accelerating factor in the development of micro-and macrovascular complications of diabetes. 29, 30 The present study was hence designed to evaluate the relation of mean platelet volume (MPV) levels with serum PON-1 activity and brachial artery diameter (BAd) and BA-IMT in diabetic patients with respect to obesity and diabetic complications.
Materials and methods
A total of 201 diabetic patients (mean age: 52.4 ± 13.4 years, 73.6% were females) were included in this study, and grouped with respect to obesity (obese: BMI ≥ 30 kg/m . Outpatients aged between 18 and 75 years, who were diagnosed and treated for T2DM (fasting blood glucose > 126 mg/dl or blood glucose level of > 200 mg/dl at random measurements or haemoglobin A1C > 6.5%), and who signed informed consents were included in the study. Patients with psychiatric disorders, cancer history, chronic renal failure, thrombocytopenia, myeloproliferative disease, chronic liver disease or hepatic failure, coronary artery disease or history of acute myocardial infarction were excluded from the study.
Written informed consent was obtained from each subject following a detailed explanation of the objectives and protocol of the study, which was conducted in accordance with the ethical principles stated in the Declaration of Helsinki and approved by the institutional ethics committee. 
Assessments

Mean platelet volume (MPV)
MPV, as a component of complete blood count test, was determined in a Coulter LH 750 auto analyser (Beckman Coulter, CA, USA). Blood samples collected in tubes with EDTA were transferred to the biochemistry laboratory within 30 minutes, and laboratory analysis was performed immediately so that time to analysis was not a confounding factor for MPV results. The expected normal range for Beckman Coulter LH 750 device was 6.9-16 fL.
Measurement of paraoxonase and arylesterase activities
Venous blood samples were collected in tubes from the antecubital vein, following an overnight fasting. The tubes were centrifuged at 2000 g (10 minutes) to remove plasma and serum. The plasma and serum samples were kept at -80°C until analysis of PON1 activity.
Paraoxonase and arylesterase activities were determined using a novel automated measurement method developed by Erel (Relassay®, Turkey). Briefly, the rate of paraoxon hydrolysis was measured by increased absorbance at 412 nm at 25°C. The PON activity is expressed as U/L serum. The coefficient of variation (CV) for individual samples was 1.8%. Arylesterase activity was measured spectrophotometrically using phenyl acetate. The reaction was initiated by the addition of the serum; the increase in absorbance was read at 270 nm. Enzymatic activity was calculated from the molar absorptivity coefficient of the produced phenol. One unit of arylesterase activity was defined as 1 μmol phenol generated/minute under defined assay conditions and expressed as U/L serum. The CV for individual serum samples was 3.3%.
Measurement of brachial artery diameter (BAd) and intima media thickness (BA-IMT)
Ultrasonography (US) examinations, IMT and brachial artery diameter measurements were performed by the same radiologist. After a five-minute rest in the supine position the brachial artery was examined in a longitudinal plane between the antecubital fossa and axilla by continuous grey-scale imaging with a linear, high resolution Dynamic Micro Slice (7-18 MHz) transducer. US examinations were performed by Toshiba Aplio 500 (Toshiba Medical Systems Corporation, Nasu, Japan). Measurement of IMT in the brachial artery was performed at the proper site, where IMT was considered the thickest, and where the clearest B mode image of the anterior and posterior intimal interfaces between the lumen and vessel wall was obtained above antecubital fossa. IMT was measured three times and the brachial IMT was defined as the mean of these three measurements. On the same image where the IMT was measured, the distance between the two intimal interfaces was measured and defined as the diameter of the brachial artery.
Statistical analysis
Statistical analysis was made using the MedCalc Statistical Software version 12.7.7 (MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2013). The Mann-Whitney U test was used to analyse independent non-parametric variables, while the Pearson and Spearman correlation analyses were performed to determine correlations between parametric and non-parametric variables, respectively. Data were expressed as 'mean ± standard deviation (SD)' , minimum-maximum and percentage (%) where appropriate. P < 0.05 was considered statistically significant.
Results
Patient characteristics
Overall, obesity was determined in 44.3% of the patients; at least one diabetic microvascular complication was evident in 50 (75.1%) patients, including neuropathy (19.4%), retinopathy (12.9%), and nephropathy (8.5%). At least one diabetic macrovascular complication was evident in 91 (45.5%) patients, including hypertension (42.8%), CAD (6.5%), past history of CABG (4.0%), PAD (1.0%), stroke (0.5%) and past history of MI (0.5%). Active smokers made up 13.9% of the study population, while regular alcohol consumption and physical activity were noted in 10% and 28.4% of patients, respectively (Table 1) .
HbA1c was 7.4 ± 1.9% and blood glucose was 148.2 ± 61.6 mg/dL in the overall study population.
MPV, paraoxonase and arylesterase levels in the study groups
Paraoxonase and arylesterase values were 119.8 ± 37.5 U/L and 149.0 ± 39.9 U/L, respectively in the overall population, with no significant difference with respect to obesity and macrovascular diabetic complications, whereas significantly lower values for paraoxonase (107.5 ± 30.7 vs. 123.9 ± 38.8 U/L, p = 0.007) and arylesterase (132.1 ± 30.2 vs. 154.7 ± 41.2 U/L, p = 0.001) were noted in patients with than in those without diabetic microvascular complications (Table 2) . values was observed in obese vs. non-obese patients, or in patients with vs. those without diabetic complications. No significant correlation was found between MPV values and PON-1 activity or BAd or BA-IMT in our study population, regardless of the obesity or diabetic complication status.
Lower PON1 activity was also shown in diabetic patients with complications, 34 including macrovascular 35, 36 and microvascular 37 complications, and especially in those with neuropathy and nephropathy, leading to a higher risk for atherosclerosis.
16
No difference was noted with regard to macrovascular complications. However, significantly lower paraoxonase and arylesterase activities in our diabetic patients with microvascular complications compared with those without microvascular complications were found to be consistent with the more pronounced decrease in PON1 activity reported in patients with, than in those without diabetic nephropathy, when compared with controls. [37] [38] [39] [40] [41] This relationship was also reported in patients with, than in those without diabetic retinopathy 39, 42, 43 as well as in the data on the lowest levels of paraoxonase specific activity in patients with peripheral neuropathy. 42 In this regard, our findings suggested that decreased PON1 activity in patients with type 2 MPV values were 9.10 ± 0.87 fL in the overall population, with no significant difference in respect of obesity and diabetic complications ( Table 2) .
Correlation of MPV values to paraoxonase and arylesterase activities in the study groups
No significant correlation of MPV values to paraoxonase and arylesterase activities was noted in the overall study population as well as in study groups of obese vs. non-obese patients, and in patients with vs. those without diabetic complications (Table 3) .
Correlation of MPV values to BAd and BA-IMT in the study groups
No significant correlation of MPV values to BAd and BA-IMT was noted in the overall study population, or in study groups of obese vs. non-obese patients and patients with vs. without diabetic complications (Table 4) .
Discussion
The study results revealed significantly lower PON-1 activity in diabetic patients with microvascular complications than in those without microvascular complications, while no difference in MPV inducing nonenzymatic glycation of proteins on the platelet surface, through the osmotic effect of glucose and activation of protein kinase C. Such glycation decreases membrane fluidity and increases the propensity of platelets to activate. [54] [55] [56] [57] Higher levels for MPV were shown in diabetic patients than in the control group, and also in diabetic patients with, than in those without retinopathy, along with a positive correlation with FBG and HbA1c levels, in another study from Turkey. 62 Moreover, MPV has been suggested to be a simple and cost-effective tool to monitor the progression and control of T2DM, and a useful prognostic marker of cardiovascular complications in patients with T2DM. 3, 60 Notably, a difference between platelet volume indices in terms of their association with macrovascular and peripheral neuropathy complications was also reported in a previous study on type 2 diabetic patients, which indicated that both MPV and platelet distribution width (PDW) were significantly associated with vibration perception threshold (VPT), while only PDW, but not MPV, was significantly associated with carotid IMT in a multivariate analysis. 63 In this regard, and although the lack of a control group limits the interpretation of our findings in relation to the above findings, MPV values were within the normal non-diabetic range in our diabetic patients with no difference in MPV values, with regard to presence of obesity or diabetic complications. Accordingly, aside from the lack of an increased platelet activity, which is one of the mechanisms deemed responsible for the pathogenesis of atherosclerosis, [24] [25] [26] no correlation of MPV levels to BAd and BA-IMT was noted in our study population.
In addition, on the basis of mean HbA1c (7.4%) and blood glucose (148.2 mg/dL) in our study population, it should be noted that platelet hyper-reactivity and increased baseline activation in patients with diabetes mellitus has been considered to be multifactorial and related to certain biochemical factors including hyperglycaemia, insulin resistance and hyperlipidaemia. 56 Several limitations to this study should be considered. First, the crosssectional nature of the study and lack of a non-diabetic control group along with the relatively small sample size precluded the possibility of drawing extensive causal conclusions and generalising our findings to the overall diabetic population. Second, no data are available considering surrogate serum biomarkers of oxidative stress alterations, which could have impacts on PON1 protein diabetes mellitus was probably playing a role in the development of diabetic vascular complications. [38] [39] [40] [41] Following the first data on decreased PON1 paraoxonase activity and increased lipid peroxidation levels in isolated HDL from obese adult patients, 44 a decreased serum PON1 arylesterase activity was consistently reported in obese adults. 45, 46 Although data on PON1 paraoxonase activity in obesity revealed inconsistent findings with decrease in activity as shown in some studies, 47 ,48 similar to our study no significant change was reported in the others. [49] [50] [51] Enhanced platelet activity has been documented, 3, 54 in relation to the fact that abnormal platelet-endothelial interaction is an essential pathogenic mechanism in the development of atherosclerosis. 52, 53 Larger platelets are younger, more reactive, contain denser granules, and secrete more serotonin and β-thromboglobulin. They have been reported to produce more thromboxane A2 than smaller platelets. All these can produce a pro-coagulant effect and cause thrombotic vascular complications. This suggests a relationship between platelet function, especially with MPV and diabetic vascular complications, thus indicating changes in MPV and reflecting the state of thrombogenesis. High MPV has currently therefore emerged as a new risk factor for the vascular complications of DM. [54] [55] [56] Significantly higher values for MPV in diabetic patients as opposed to non-diabetic subjects have consistently been reported in previous studies, with regard to an increased thrombotic state. 3, 29, 30, [57] [58] [59] Data from different cohorts of type 2 diabetes mellitus patients in Turkey revealed significantly higher values for MPV in diabetics compared with age-and sex-matched nondiabetic healthy controls, 29, 60 and also in diabetics and subjects with impaired fasting glucose compared with the non-diabetic group, along with a positive correlation of MPV with HbA1c and fasting blood glucose (FBG) levels. 60 Similarly, in another study from Turkey, MPV levels were reported to be significantly higher in type 2 diabetic patients with HbA1c levels > 7% than in patients with HbA1c levels ≤ 7% and in nondiabetics, 3 which is consistent with the statement that glycaemic control reduces MPV levels and hence the possible role of platelets in cardiovascular events observed in type 2 diabetic patients. 61 Hyperglycaemia can increase platelet reactivity by 
